Glenmark Q4 FY 2020-21 revenue grows 3.3%; Net profit up 6.2%
For the year ended March 31, 2021, consolidated revenue was at Rs. 10,943.9 crores as against Rs. 10,641 crores, recording an increase of 2.8% over the previous corresponding period
For the year ended March 31, 2021, consolidated revenue was at Rs. 10,943.9 crores as against Rs. 10,641 crores, recording an increase of 2.8% over the previous corresponding period
The roller coaster ride during the pandemic has taken Indian pharmaceutical industry through a lot of bitter sweet experiences.
This marks Glenmark's first synthetic decapeptide injectable approval
The company plans to enter the EU markets in FY22
Nanoform and Celanese intend to work on formulation development, leveraging each organization's unique formulation expertise.
NATCO Pharmaceuticals, Hyderabad; Alembic Pharmaceuticals, Vadodara; Gufic Biosciences Ltd., Gujarat; Emcure Pharmaceuticals, Pune; and Lyka, Gujarat are new manufacturers
Allecra Therapeutics would now either directly or through out license file for NDA of this molecule.
Drop in revenue in the fourth quarter is normal as China is shut down for most of the quarter due to the Chinese New Year holiday
Lurasidone Hydrochloride tablets are also indicated for adjunctive treatment with lithium or valproate in adult patients with major depressive episode associated with bipolar I disorder
The agreement will help ensure wider reach and access to patients in India
Subscribe To Our Newsletter & Stay Updated